OBI Pharma, Inc.

OBI Pharma, Inc. is a biotechnology company specializing in the research and development of innovative cancer therapies. Founded in 2002 and headquartered in Taipei, Taiwan, OBI Pharma operates as a global clinical-stage oncology firm with subsidiaries in the United States and Australia. Its core mission is to create novel therapeutic agents that address unmet medical needs in oncology, particularly through the development of "first-in-class" and "best-in-class" drug candidates. The company has a robust pipeline of products in various stages, including investigational therapies for triple-negative breast cancer, non-small cell lung cancer, hepatocellular carcinoma, and solid tumors. Recognized for its cutting-edge work in antibody-drug conjugates (ADC) and immunotherapy, OBI Pharma has received industry awards highlighting the promise of its technology and research platforms. Beyond oncology, OBI Pharma is engaged in the manufacture, wholesale, and global licensing of pharmaceutical products, contributing to advancements in the broader biotechnology and healthcare sectors. The company prioritizes both scientific excellence and international growth, reinforcing Taiwan’s emerging presence in global pharmaceutical innovation.